Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis.

Journal Article (Journal Article)

PURPOSE: To report two cases in which a bull's eye maculopathy developed after intravitreal injection of fomivirsen. METHODS: Case reports. RESULTS: A 50-year-old man with acquired immunodeficiency syndrome (AIDS) and refractory cytomegalovirus retinitis developed bull's-eye pigmentary changes in the macula of the right eye after initiating therapy with fomivirsen (Vitravene; CIBA Vision, Atlanta, Georgia) intravitreal injections. These pigmentary changes resolved upon cessation of treatment. A 36-year-old man with AIDS and refractory bilateral cytomegalovirus retinitis developed bull's-eye pigmentary changes in both eyes during bilateral intravitreal treatment with fomivirsen. Vision was not affected. These changes resolved after treatment with fomivirsen was stopped. CONCLUSION: Fomivirsen, a new medication for the treatment of refractory cytomegalovirus retinitis, may cause a bull's-eye maculopathy in some patients. The bull's-eye maculopathy is reversible and does not appear to affect vision.

Full Text

Duke Authors

Cited Authors

  • Stone, TW; Jaffe, GJ

Published Date

  • August 2000

Published In

Volume / Issue

  • 130 / 2

Start / End Page

  • 242 - 243

PubMed ID

  • 11004306

International Standard Serial Number (ISSN)

  • 0002-9394

Digital Object Identifier (DOI)

  • 10.1016/s0002-9394(00)00495-5


  • eng

Conference Location

  • United States